Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study

Arjun V. Balar, Ashish M. Kamat, Girish S. Kulkarni, Edward M. Uchio, Joost L. Boormans, Mathieu Roumiguié, Laurence E.M. Krieger, Eric A. Singer, Dean F. Bajorin, Petros Grivas, Ho Kyung Seo, Hiroyuki Nishiyama, Badrinath R. Konety, Haojie Li, Kijoeng Nam, Ekta Kapadia, Tara Frenkl, Ronald de Wit

Research output: Contribution to journal › Article › peer-review

234 Scopus citations

Fingerprint

Dive into the research topics of 'Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study'. Together they form a unique fingerprint.

Medicine & Life Sciences